Strattera (Atomoxetine) vs Wellbutrin (Bupropion) — Key Takeaways: Non-Stimulant ADHD, CYP2D6, and the Depression Fork

📇 The Index Card — Key Takeaways

Strattera (Atomoxetine) vs Wellbutrin (Bupropion)

The fork in the road. Picture two patients who get lumped together because both struggle to focus. One has ADHD as the central, most impairing problem and stimulants are not an option. The other is depressed — sleeping too much, gaining weight, nothing enjoyable — with a whiff of executive dysfunction tangled up in the depression. Same waiting room, two different prescriptions.

1. Strattera is second-line for ADHD — by design. Stimulants — the methylphenidate and amphetamine families, in every patch, liquid, and bead formulation — remain first-line and the most efficacious option. NP Z reaches for atomoxetine when stimulants are off the table: a prior trial the patient refuses to repeat, non-response, a stated preference for a non-stimulant, or individual concerns such as diversion, misuse, or psychosis risk.
2. The trade is speed for coverage. A stimulant can start helping within about an hour. Atomoxetine takes weeks, plus dose optimization, before it kicks in — and GI side effects can show up first. The payoff once it is optimized: non-habit-forming, around-the-clock coverage. A stimulant that runs 6 a.m. to 4 p.m. leaves the commute home, dinner, and the taxes uncovered; atomoxetine does not wear off at a particular time of day.
3. Same neighborhood, different jobs — and different FDA labels. Atomoxetine is a selective norepinephrine reuptake inhibitor (it blocks the pump that clears norepinephrine, so more stays active) that secondarily raises dopamine in the prefrontal cortex. Bupropion is an NDRI — a norepinephrine-dopamine reuptake inhibitor. Per the FDA labels, Strattera is approved for ADHD; Wellbutrin is approved for depression and smoking cessation — not for ADHD.
4. CYP2D6 is why Strattera's tiny dose steps matter. Atomoxetine is cleared by CYP2D6, a liver enzyme patients carry in different versions. Poor metabolizers can carry roughly 10 times the expected drug level — and the side effects that come with it — while rapid metabolizers may barely register a starting dose. That is why the fine increments (10 mg, 18 mg, and upward toward a 100 mg max, with response often at 40 mg and above) and a low-and-slow titration matter, and why the FDA Strattera label raises considering genetic testing when side effects or non-response are puzzling.
5. Wellbutrin's ideal patient is depressed first. Sleeping in, gaining weight, anhedonic, wanting to get to the gym but unable to get moving — that low-drive, hypersomnic picture (sleeping too much) is where this activating NDRI fits, with a weight profile that is generally weight-neutral and can include some weight loss. If executive dysfunction rides underneath the depression, improvement there is a genuine two-for-one. NP Z's analogy: at McDonald's you go for the burger, not the fish sandwich — depression is Wellbutrin's burger; ADHD help is the fish sandwich. For Strattera it is reversed.
6. Anxiety is a caution, and two histories are hard stops. Many patients feel more jittery on Wellbutrin — NP Z's patients describe it as a cup-of-coffee feeling, with more irritability or anxiety for some — so prominent anxiety calls for caution rather than reaching for it first; a smaller group reports less anxiety, which NP Z suspects reflects tighter executive control and less rumination, not a direct anxiolytic effect. Per the FDA label, a seizure disorder or a current or prior diagnosis of anorexia or bulimia contraindicates Wellbutrin because of seizure risk. For Strattera, watch liver impairment and its mild heart rate and blood pressure elevation — check vitals.

The call: ADHD is the central problem and stimulants are off the table → Strattera. Depression leads, with hypersomnia and weight gain → Wellbutrin. And the episode's closing pearl — Strattera is the FDA-approved non-stimulant to reach for when stimulants are off the table; Wellbutrin's home turf is depression — its executive-function help is the side benefit, not the main event.